Multiple myeloma is still an incurable disease. The standard conventional chemotherapy comprises melphalan and prednisone (MP). Combination chemotherapy regimens could not improve the median survival of 36 months observed with MP. In the French IFM90 study, HD therapy with TBI plus melphalan 140 mg/m 2 was shown to prolong overall survival and progression-free survival compared to conventional treatment. Nonetheless, most patients eventually succumb due to disease progression. Allogeneic transplantation may induce long-term remissions and even cure, but is hampered by a high transplantation-related mortality (TRM). Currently, efforts are made to reduce this TRM and to evaluate the graft-versus-myeloma effect. Bone Marrow Transplantation (2000) 25, Suppl. 2, S25-S26. Keywords: high-dose therapy; autologous transplantation; allogeneic transplantation Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells in the bone marrow producing a monoclonal immunglobulin that can be detected in the serum and/or urine. The incidence in the United States and in Europe is four out of 100 000 with a median age at diagnosis of 65 years at diagnosis. The standard conventional therapy is the combination of melphalan and prednisone, resulting in a response rate of 40-60% and a median survival time of about 3 years. In order to improve the therapeutic efficacy various combination regimens have been tested. Unfortunately, most randomized trials have failed to show a significant improvement in survival time when combination chemotherapy is used instead of melphalan with or without prednisone.
Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells in the bone marrow producing a monoclonal immunglobulin that can be detected in the serum and/or urine. The incidence in the United States and in Europe is four out of 100 000 with a median age at diagnosis of 65 years at diagnosis. The standard conventional therapy is the combination of melphalan and prednisone, resulting in a response rate of 40-60% and a median survival time of about 3 years. In order to improve the therapeutic efficacy various combination regimens have been tested. Unfortunately, most randomized trials have failed to show a significant improvement in survival time when combination chemotherapy is used instead of melphalan with or without prednisone. 1 Recently, myeloma treatment has been modified. Increasingly, high-dose (HD) chemotherapy accompanied by hematopoietic stem cell support via autologous or allogeneic transplant is used.
Autologous stem cell transplantation
HD chemoradiotherapy followed by either autologous bone marrow transplantation (ABMT) or autologous peripheral Correspondence: Dr H Goldschmidt, Department of Internal Medicine V, University of Heidelberg, Hospitalstr. 3, 69115 Heidelberg, Germany blood stem cell transplantation (PBSCT) has increased the rate of complete responses (CR) from 15% (after conventional therapy) to 40%. The median duration of these responses has been only 24-36 month at best. 2 The results of the IMF-90 3 trial showed a significantly longer eventfree survival (EFS) and overall survival (OS) in patients treated with HD melphalan and total body irradiation (TBI) followed by ABMT compared to patients treated with conventional chemotherapy (Table 1) . Between 1992 and 1996, 100 patients were transplanted at our center. PBSC were collected during G-CSF-enhanced leukocyte recovery following HD chemotherapy. Fifty patients were treated with TBI + melphalan 140 mg/m 2 , while 50 patients received melphalan 200 mg/m 2 alone. Following PBSCT the median time to reach platelets Ͼ20 × 10 9 /l and neutrophils Ͼ0.5 × 10 9 /l was 11 and 14 days, respectively, with no significant difference between the treated groups. In the TBI group significantly longer periods of parenteral nutrition were required due to transplantation-related complications. Following HD treatment remission state improved in 43 out of 98 patients. No significant advantage in reaching CR or PR was observed with TBI + HD melphalan compared to the treatment with HD melphalan alone. 4 In order to further improve treatment results we started a multicentre phase II study to evaluate a sequential HD therapy in 1996. Similar to the 'total therapy', introduced by Barlogie et al, 5 we used a tandem HD melphalan approach. 6 The mortality of the mobilization and transplantation in this trial was 2.1%. Forty percent of the patients had a CR according to the EBMT criteria. The French IFM-94 study demonstrated a clinical benefit for a subgroup of patients with low beta2- microglobulin using sequential in comparison to single HD therapy. 7 In a subsequent trial (Figure 1) we will compare the toxicities and the long-term outcome of patients undergoing one cycle vs two cycles of HD melphalan.
Attempts are underway to improve the outcome of autografting. Studies include the purging of autografts, maintenance treatments with different dosages of alpha-interferon or chemotherapy, vaccination or immune-based therapies 2 and additional therapy with thalidomide. 
Allogeneic stem cell transplantation
Enthusiasm for allogeneic transplantation in patients with MM has been hampered by a transplant-related mortality (TRM) of up to 50% in the first year after transplantation. The rate of relapses though is lower compared to autografting. 9 After allogeneic transplantation some patients live for more than 10 years without any sign of disease using allelespecific oligonucleotide PCR as the detector. Using ASO-PCR techniques one cell of the myeloma clone can be detected in up to 330 000 bone marrow or peripheral blood mononuclear cells. Major causes of death after allogeneic transplantation are infections as well as graft-versus-host disease (GVHD). An EBMT 10 case-matched analysis between 25 syngeneic transplants and 125 allogeneic and 125 autologous cases, respectively, has shown that survival following syngeneic transplantation tended to be superior to that of autologous transplantation and was significantly better than that of allogeneic transplantation. The OS 4 years after syngeneic transplantation was 77%, after allogeneic transplantation 31% and after autotransplantation 46%. The reason for the better outcome after syngeneic transplantation compared to allogeneic transplantation was the lower rate of treatment-related deaths. To reduce the TRM, Russel et al 11 have used fractionated TBI combined with melphalan (110 mg/m 2 ) for conditioning in the allogeneic setting. This is a lower dose of melphalan than the one which is used conventionally for autologous transplantation. The aim of this attempt is to reduce mucosal and other organ toxicity in patients who are also receiving posttransplant GVHD prophylaxis with a short course of MTX and cyclosporin. Since 1991, 24 patients have been transplanted, 23 from sibling donors and one from an unrelated donor. The OS is 70% at 5 years. Seventeen of 18 evaluable patients have achieved CR, although in four cases this was only achieved following a course of post-transplant interferon. Recently Gahrton et al 10 summarized the allogeneic EBMT data and concluded that the outcome after transplantation does not differ significantly using peripheral blood stem cells or bone marrow. However, the transplant-related mortality was reduced in the last 5 years compared to the data before 1994. Most excitingly, the use of donor lymphocyte infusion (DLI) to treat patients with relapsed MM after allografting has provided unequivocal evidence of an allogeneic graft-versus-myeloma effect. Lockhorst et al 12 showed that eight of 13 patients treated with DLI for relapsed MM post-allografting responded, including four CR and four PR. Efforts to reduce the TRM and to evaluate the graft-versus-myeloma effect should continue.
